Premium
P4‐435: A pilot phase IV open label study investigating the safety and tolerability of switching from the Exelon patch 9.5mg daily to Aricept 23mg daily in patients with moderate to severe AD
Author(s) -
Sabbagh Marwan,
Syal Atul,
Obradov Zoran,
Kahlon Maninder,
Jacobson Sandra,
Shah Jatin,
Liebsack Carolyn,
Belden Christine,
Shutts Tammy,
MalekAhmadi Michael,
Kratz Kris,
Klinck Brian
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.09.131
Subject(s) - donepezil , tolerability , rivastigmine , medicine , adverse effect , placebo , dementia , regimen , pharmacology , disease , alternative medicine , pathology